Presentation is loading. Please wait.

Presentation is loading. Please wait.

Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation  Stefan O. Ciurea,

Published byMario Carrasco Modified over 4 years ago

Similar presentations

Presentation on theme: "Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation  Stefan O. Ciurea,"— Presentation transcript:

1 Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation  Stefan O. Ciurea, Victor Mulanovich, Rima M. Saliba, Ulas D. Bayraktar, Ying Jiang, Roland Bassett, Sa A. Wang, Marina Konopleva, Marcelo Fernandez-Vina, Nivia Montes, Doyle Bosque, Julianne Chen, Gabriela Rondon, Gheath Alatrash, Amin Alousi, Qaiser Bashir, Martin Korbling, Muzaffar Qazilbash, Simrit Parmar, Elizabeth Shpall, Yago Nieto, Chitra Hosing, Partow Kebriaei, Issa Khouri, Uday Popat, Marcos de Lima, Richard E. Champlin  Biology of Blood and Marrow Transplantation  Volume 18, Issue 12, Pages (December 2012) DOI: /j.bbmt Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Outcomes of T cell replete (TCR) and T cell depleted (TCD) haploidentical transplant patients treated with fludarabine, melphalan, and thiotepa conditioning. (A) Progression-free survival for all patients. (B) Progression-free survival for patients in remission at transplantation. (C) Non-relapse mortality for all patients. (D) Non-relapse mortality for patients in remission at transplantation. (E) Cumulative incidence of chronic graft-versus-host disease (cGVHD). (F) Cumulative incidence of grade II-IV acute graft-versus-host disease (aGVHD). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Recovery of T cell subsets after transplant in T cell replete (TCR) and T cell depleted (TCD) haploidentical stem cell transplantations. **P < .002 (with Bonferroni correction); *P > .002 < .05. (A) Recovery of absolute CD8+ cell numbers (median). (B) Recovery of absolute CD4+ cell numbers (median). (C) Recovery of absolute CD4+CD45RA+ cell numbers (naive T cells) (median). (D) Recovery of absolute CD4+CD45RO+ cell numbers (memory T cells) (median). (E) Recovery of absolute CD56+ cell numbers (natural killer [NK] cells) (median). (F) Recovery of absolute CD19+ cell numbers (B cells) (median). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation  Stefan O. Ciurea,"

Similar presentations

Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation  Li Mei Poon, Amir Hamdi, Rima.

Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation  Li Mei Poon, Amir Hamdi, Rima.
Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed.

Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed.
Haploidentical Transplantation with Post-transplant Cyclophosphamide and Melphalan-based Conditioning– A retrospective Analysis of the First 100 Patients.

Haploidentical Transplantation with Post-transplant Cyclophosphamide and Melphalan-based Conditioning– A retrospective Analysis of the First 100 Patients.
Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.

Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.
Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation  Li Mei Poon, Amir Hamdi, Rima.

Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation  Li Mei Poon, Amir Hamdi, Rima.
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction  Muzaffar H. Qazilbash, Ali Imran.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction  Muzaffar H. Qazilbash, Ali Imran.
Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation  Maria R. Khouri, Elias J. Jabbour, Alison.

Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation  Maria R. Khouri, Elias J. Jabbour, Alison.
Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.
Muzaffar H. Qazilbash, MD, Peter Thall, PhD, Patricia S

Muzaffar H. Qazilbash, MD, Peter Thall, PhD, Patricia S
High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid.

High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid.
Clofarabine ± Fludarabine with Once Daily i. v

Clofarabine ± Fludarabine with Once Daily i. v
Outcome of Patients with Multiple Myeloma by Ethnicity in the Setting of Autologous Stem Cell Transplant  Koji Sasaki, MD, Qaiser Bashir, MD, Nina Shah,

Outcome of Patients with Multiple Myeloma by Ethnicity in the Setting of Autologous Stem Cell Transplant  Koji Sasaki, MD, Qaiser Bashir, MD, Nina Shah,
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
Moderate Renal Function Impairment Does Not Affect Outcomes of Reduced-Intensity Conditioning with Fludarabine and Melphalan for Allogeneic Hematopoietic.

Moderate Renal Function Impairment Does Not Affect Outcomes of Reduced-Intensity Conditioning with Fludarabine and Melphalan for Allogeneic Hematopoietic.
T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL) 

T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL) 
Clinical Outcomes of Multiple Myeloma Patients with TP53 Gene Deletion after Autologous Stem Cell Transplantation: The MD Anderson Cancer Center Experience 

Clinical Outcomes of Multiple Myeloma Patients with TP53 Gene Deletion after Autologous Stem Cell Transplantation: The MD Anderson Cancer Center Experience 
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes 

Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes 
Long-Term Follow-Up of Patients Who Experienced Graft Failure Postallogeneic Progenitor Cell Transplantation. Results of a Single Institution Analysis 

Long-Term Follow-Up of Patients Who Experienced Graft Failure Postallogeneic Progenitor Cell Transplantation. Results of a Single Institution Analysis 
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine,

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine,
Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.

Similar presentations

Ads by Google